Clinical data of 8 cases of extranodal MALT-type MZBCL characterized by t(11;18)(q21;q21) as shown by FISH
| Case . | Sex/Age, y . | Clinical stage . | Tumor localization . | Treatment/Response . | DFS/OS, mo . |
|---|---|---|---|---|---|
| 1 | M/52 | IE1 | stomach | gastrectomy/CR | 102/102 |
| 2 | F/42 | IE1 | stomach | gastrectomy/CR | 109/109 |
| 3 | F/56 | IE1 | ileum | tumor resection, CT/SD | 0/80 |
| 4 | M/54 | IIE1 | stomach, perigastric LN, omentum | extended gastrectomy/CR | 26/26 |
| 5 | F/62 | IIIES | stomach, spleen | gastrectomy, splenectomy, RT/CR | 106/106 |
| 6* | M/46 | IVE | stomach, small and large intestine, mesenteric LN | CT, H pylori eradication therapy/CR | 23/28 |
| 7 | M/58 | IVE | stomach, BM | Gastrectomy, CT/CR | 24/24 LFU |
| 8* | F/28 | IVE | stomach, spleen, BM, PB | Splenectomy, H pylori eradication therapy/SD | 0/20 |
| Case . | Sex/Age, y . | Clinical stage . | Tumor localization . | Treatment/Response . | DFS/OS, mo . |
|---|---|---|---|---|---|
| 1 | M/52 | IE1 | stomach | gastrectomy/CR | 102/102 |
| 2 | F/42 | IE1 | stomach | gastrectomy/CR | 109/109 |
| 3 | F/56 | IE1 | ileum | tumor resection, CT/SD | 0/80 |
| 4 | M/54 | IIE1 | stomach, perigastric LN, omentum | extended gastrectomy/CR | 26/26 |
| 5 | F/62 | IIIES | stomach, spleen | gastrectomy, splenectomy, RT/CR | 106/106 |
| 6* | M/46 | IVE | stomach, small and large intestine, mesenteric LN | CT, H pylori eradication therapy/CR | 23/28 |
| 7 | M/58 | IVE | stomach, BM | Gastrectomy, CT/CR | 24/24 LFU |
| 8* | F/28 | IVE | stomach, spleen, BM, PB | Splenectomy, H pylori eradication therapy/SD | 0/20 |
The clinical stage given is based on the Musshoff classification. DFS indicates disease-free survival; OS, overall survival; CR, complete remission; CT, chemotherapy; SD, stable disease; RT, radiotherapy; LN, lymph node; BM, bone marrow; LFU, lost to follow-up; and PB, peripheral blood.
These cases have been included in a previous publication.6